This study is looking at how continuing or stopping GLP-1 receptor agonists (a type of medication that helps regulate blood sugar and appetite) after weight-loss surgery affects people with morbid obesity, metabolic syndrome, diabetes, high blood pressure, or sleep apnea. You could join if you are over 18, having weight-loss surgery at MU Health Care, and currently taking a GLP-1 receptor agonist. The researchers want to see how these medications impact weight loss, certain substances in your blood (circulating bile acids and metabolites), and the types of bacteria in your gut (gut microbiome diversity) six months after surgery. The current recruitment status is unclear.

Study design

This interventional study plans to enroll 150 participants who will be randomly assigned to either continue or discontinue GLP-1 receptor agonists after bariatric surgery.

What's involved

Recruitment occurs at the preoperative education class. Participants will be randomized to either continue or discontinue GLP-1 receptor agonists.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 6 months to measure weight loss, circulating bile acids and metabolites, and gut microbiome diversity.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.